New-onset type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis associated with type 1 interferon therapy for chronic hepatitis C. 2012

Tomoya Kawazoe, and Manabu Araki, and Youwei Lin, and Masafumi Ogawa, and Tomoko Okamoto, and Takashi Yamamura, and Masato Wakakura, and Miho Murata
Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan.

A 60-year-old woman developed type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis during type 1 interferon therapies for chronic hepatitis C. The diabetes mellitus was elicited by interferon-α plus ribavirin therapy, while the optic neuritis was induced after interferon-β treatment, followed by interferon-α and ribavirin therapy. It is possible that type 1 interferons lead to the onset of the two autoimmune diseases by inducing disease-specific autoantibodies. Autoimmune disease is an infrequent complication of type 1 interferon treatment; however, once it has occurred, it may result in severe impairments. Patients undergoing type 1 interferon therapy should therefore be carefully monitored for any manifestations of autoimmune diseases.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009902 Optic Neuritis Inflammation of the optic nerve. Commonly associated conditions include autoimmune disorders such as MULTIPLE SCLEROSIS, infections, and granulomatous diseases. Clinical features include retro-orbital pain that is aggravated by eye movement, loss of color vision, and contrast sensitivity that may progress to severe visual loss, an afferent pupillary defect (Marcus-Gunn pupil), and in some instances optic disc hyperemia and swelling. Inflammation may occur in the portion of the nerve within the globe (neuropapillitis or anterior optic neuritis) or the portion behind the globe (retrobulbar neuritis or posterior optic neuritis). Neuropapillitis,Retrobulbar Neuritis,Anterior Optic Neuritis,Posterior Optic Neuritis,Anterior Optic Neuritides,Neuritides, Anterior Optic,Neuritides, Optic,Neuritides, Posterior Optic,Neuritides, Retrobulbar,Neuritis, Anterior Optic,Neuritis, Optic,Neuritis, Posterior Optic,Neuritis, Retrobulbar,Neuropapillitides,Optic Neuritides,Optic Neuritides, Anterior,Optic Neuritides, Posterior,Optic Neuritis, Anterior,Optic Neuritis, Posterior,Posterior Optic Neuritides,Retrobulbar Neuritides
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000888 Antibodies, Anti-Idiotypic Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies. Anti-Antibodies,Anti-Idiotype Antibodies,Antibodies, Internal Image,Antigamma Globulin Antibodies,Antiglobulins,Anti Antibodies,Anti-gamma Globulin Antibodies,Anti Idiotype Antibodies,Anti gamma Globulin Antibodies,Anti-Idiotypic Antibodies,Antibodies, Anti,Antibodies, Anti Idiotypic,Antibodies, Anti-Idiotype,Antibodies, Anti-gamma Globulin,Antibodies, Antigamma Globulin,Globulin Antibodies, Anti-gamma,Globulin Antibodies, Antigamma,Image Antibodies, Internal,Internal Image Antibodies
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

Tomoya Kawazoe, and Manabu Araki, and Youwei Lin, and Masafumi Ogawa, and Tomoko Okamoto, and Takashi Yamamura, and Masato Wakakura, and Miho Murata
August 2009, Acta ophthalmologica,
Tomoya Kawazoe, and Manabu Araki, and Youwei Lin, and Masafumi Ogawa, and Tomoko Okamoto, and Takashi Yamamura, and Masato Wakakura, and Miho Murata
August 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics,
Tomoya Kawazoe, and Manabu Araki, and Youwei Lin, and Masafumi Ogawa, and Tomoko Okamoto, and Takashi Yamamura, and Masato Wakakura, and Miho Murata
January 2018, Seminars in ophthalmology,
Tomoya Kawazoe, and Manabu Araki, and Youwei Lin, and Masafumi Ogawa, and Tomoko Okamoto, and Takashi Yamamura, and Masato Wakakura, and Miho Murata
September 2021, Japanese journal of ophthalmology,
Tomoya Kawazoe, and Manabu Araki, and Youwei Lin, and Masafumi Ogawa, and Tomoko Okamoto, and Takashi Yamamura, and Masato Wakakura, and Miho Murata
April 2019, Neuro-ophthalmology (Aeolus Press),
Tomoya Kawazoe, and Manabu Araki, and Youwei Lin, and Masafumi Ogawa, and Tomoko Okamoto, and Takashi Yamamura, and Masato Wakakura, and Miho Murata
August 2012, Journal of neurology,
Tomoya Kawazoe, and Manabu Araki, and Youwei Lin, and Masafumi Ogawa, and Tomoko Okamoto, and Takashi Yamamura, and Masato Wakakura, and Miho Murata
March 2004, Ugeskrift for laeger,
Tomoya Kawazoe, and Manabu Araki, and Youwei Lin, and Masafumi Ogawa, and Tomoko Okamoto, and Takashi Yamamura, and Masato Wakakura, and Miho Murata
March 2012, Journal of clinical and experimental hepatology,
Tomoya Kawazoe, and Manabu Araki, and Youwei Lin, and Masafumi Ogawa, and Tomoko Okamoto, and Takashi Yamamura, and Masato Wakakura, and Miho Murata
November 2018, The neurologist,
Tomoya Kawazoe, and Manabu Araki, and Youwei Lin, and Masafumi Ogawa, and Tomoko Okamoto, and Takashi Yamamura, and Masato Wakakura, and Miho Murata
February 2021, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis,
Copied contents to your clipboard!